{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:19:28Z","timestamp":1792181968322,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T00:00:00Z","timestamp":1467590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T00:00:00Z","timestamp":1467590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,2,9]]},"DOI":"10.1038\/onc.2016.244","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T10:11:13Z","timestamp":1467627073000},"page":"766-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma"],"prefix":"10.1038","volume":"36","author":[{"given":"F","family":"Cidre-Aranaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T G P","family":"Gr\u00fcnewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-7859","authenticated-orcid":false,"given":"D","family":"Surdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Carlos L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Gonz\u00e1lez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Garc\u00eda-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S E","family":"L\u00f3pez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Monz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Delattre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-8391","authenticated-orcid":false,"given":"J","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,4]]},"reference":[{"key":"BFonc2016244_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4161\/cbt.9.9.11511","volume":"9","author":"C Mackintosh","year":"2010","unstructured":"Mackintosh C, Madoz-Gurpide J, Ordonez JL, Osuna D, Herrero-Martin D . The molecular pathogenesis of Ewing\u2019s sarcoma. Cancer Biol Ther 2010; 9: 655\u2013667.","journal-title":"Cancer Biol Ther"},{"key":"BFonc2016244_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.pharmthera.2012.10.004","volume":"137","author":"PJ Grohar","year":"2013","unstructured":"Grohar PJ, Helman LJ . Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther 2013; 137: 216\u2013224.","journal-title":"Pharmacol Ther"},{"key":"BFonc2016244_CR3","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","volume":"28","author":"R Ladenstein","year":"2010","unstructured":"Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28: 3284\u20133291.","journal-title":"J Clin Oncol"},{"key":"BFonc2016244_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fonc.2013.00230","volume":"3","author":"L Zhu","year":"2013","unstructured":"Zhu L, McManus MM, Hughes DP . Understanding the biology of bone sarcoma from early initiating events through late events in metastasis and disease progression. Front Oncol 2013; 3: 230.","journal-title":"Front Oncol"},{"key":"BFonc2016244_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/359162a0","volume":"359","author":"O Delattre","year":"1992","unstructured":"Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162\u2013165.","journal-title":"Nature"},{"key":"BFonc2016244_CR6","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1517\/14728222.2014.947963","volume":"18","author":"H Kovar","year":"2014","unstructured":"Kovar H . Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS\/FLI-1 fusion in Ewing sarcoma as novel therapy. Expert Opin Ther Targets 2014; 18: 1315\u20131328.","journal-title":"Expert Opin Ther Targets"},{"key":"BFonc2016244_CR7","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1158\/1078-0432.CCR-06-1762","volume":"13","author":"J Carrillo","year":"2007","unstructured":"Carrillo J, Garcia-Aragoncillo E, Azorin D, Agra N, Sastre A, Gonzalez-Mediero I et al. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 2007; 13: 2429\u20132440.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016244_CR8","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1038\/onc.2008.203","volume":"27","author":"E Garcia-Aragoncillo","year":"2008","unstructured":"Garcia-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gomez-Lopez G, Pestana A et al. DAX1, a direct target of EWS\/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing\u2019s tumor cells. Oncogene 2008; 27: 6034\u20136043.","journal-title":"Oncogene"},{"key":"BFonc2016244_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ccr.2006.04.004","volume":"9","author":"R Smith","year":"2006","unstructured":"Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR et al. Expression profiling of EWS\/FLI identifies NKX2.2 as a critical target gene in Ewing\u2019s sarcoma. Cancer Cell 2006; 9: 405\u2013416.","journal-title":"Cancer Cell"},{"key":"BFonc2016244_CR10","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-12-0371","volume":"72","author":"D Surdez","year":"2012","unstructured":"Surdez D, Benetkiewicz M, Perrin V, Han ZY, Pierron G, Ballet S et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-beta abolishes ewing sarcoma growth. Cancer Res 2012; 72: 4494\u20134503.","journal-title":"Cancer Res"},{"key":"BFonc2016244_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1541-7786.MCR-11-0524","volume":"10","author":"TG Grunewald","year":"2012","unstructured":"Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U et al. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res 2012; 10: 52\u201365.","journal-title":"Mol Cancer Res"},{"key":"BFonc2016244_CR12","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1128\/MCB.24.16.7275-7283.2004","volume":"24","author":"A Prieur","year":"2004","unstructured":"Prieur A, Tirode F, Cohen P, Delattre O . EWS\/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004; 24: 7275\u20137283.","journal-title":"Mol Cell Biol"},{"key":"BFonc2016244_CR13","doi-asserted-by":"publisher","first-page":"e66281","DOI":"10.1371\/journal.pone.0066281","volume":"8","author":"N Agra","year":"2013","unstructured":"Agra N, Cidre F, Garcia-Garcia L, de la Parra J, Alonso J . Lysyl oxidase is downregulated by the EWS\/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in ewing sarcoma cells. PLoS One 2013; 8: e66281.","journal-title":"PLoS One"},{"key":"BFonc2016244_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/carcin\/bgp317","volume":"31","author":"D Navarro","year":"2010","unstructured":"Navarro D, Agra N, Pestana A, Alonso J, Gonzalez-Sancho JM . The EWS\/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin\/TCF-mediated transcription. Carcinogenesis 2010; 31: 394\u2013401.","journal-title":"Carcinogenesis"},{"key":"BFonc2016244_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/13854","volume":"23","author":"KB Hahm","year":"1999","unstructured":"Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999; 23: 222\u2013227.","journal-title":"Nat Genet"},{"key":"BFonc2016244_CR16","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1242\/dev.126.20.4465","volume":"126","author":"G Minowada","year":"1999","unstructured":"Minowada G, Jarvis LA, Chi CL, Neubuser A, Sun X, Hacohen N et al. Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development 1999; 126: 4465\u20134475.","journal-title":"Development"},{"key":"BFonc2016244_CR17","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1242\/jcs.00652","volume":"116","author":"GR Guy","year":"2003","unstructured":"Guy GR, Wong ES, Yusoff P, Chandramouli S, Lo TL, Lim J et al. Sprouty: how does the branch manager work? J Cell Sci 2003; 116: 3061\u20133068.","journal-title":"J Cell Sci"},{"key":"BFonc2016244_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ncb0503-377","volume":"5","author":"G Christofori","year":"2003","unstructured":"Christofori G . Split personalities: the agonistic antagonist Sprouty. Nat Cell Biol 2003; 5: 377\u2013379.","journal-title":"Nat Cell Biol"},{"key":"BFonc2016244_CR19","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1101\/gad.1940710","volume":"24","author":"Z Zhao","year":"2010","unstructured":"Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010; 24: 1389\u20131402.","journal-title":"Genes Dev"},{"key":"BFonc2016244_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1677\/erc.1.01190","volume":"13","author":"S Fritzsche","year":"2006","unstructured":"Fritzsche S, Kenzelmann M, Hoffmann MJ, Muller M, Engers R, Grone HJ et al. Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer 2006; 13: 839\u2013849.","journal-title":"Endocr Relat Cancer"},{"key":"BFonc2016244_CR21","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1158\/0008-5472.CAN-04-1207","volume":"64","author":"TL Lo","year":"2004","unstructured":"Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA et al. The ras\/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 2004; 64: 6127\u20136136.","journal-title":"Cancer Res"},{"key":"BFonc2016244_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4161\/epi.4.1.7400","volume":"4","author":"B Kwabi-Addo","year":"2009","unstructured":"Kwabi-Addo B, Ren C, Ittmann M . DNA methylation and aberrant expression of Sprouty1 in human prostate cancer. Epigenetics 2009; 4: 54\u201361.","journal-title":"Epigenetics"},{"key":"BFonc2016244_CR23","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1158\/0008-5472.CAN-03-3759","volume":"64","author":"B Kwabi-Addo","year":"2004","unstructured":"Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004; 64: 4728\u20134735.","journal-title":"Cancer Res"},{"key":"BFonc2016244_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1757-2215-7-61","volume":"7","author":"S Masoumi-Moghaddam","year":"2014","unstructured":"Masoumi-Moghaddam S, Amini A, Ehteda A, Wei AQ, Morris DL . The expression of the Sprouty 1 protein inversely correlates with growth, proliferation, migration and invasion of ovarian cancer cells. J Ovarian Res 2014; 7: 61.","journal-title":"J Ovarian Res"},{"key":"BFonc2016244_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603\u2013607.","journal-title":"Nature"},{"key":"BFonc2016244_CR26","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/ng.3363","volume":"47","author":"TG Grunewald","year":"2015","unstructured":"Grunewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM et al. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet 2015; 47: 1073\u20131078.","journal-title":"Nat Genet"},{"key":"BFonc2016244_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/boc.201300011","volume":"105","author":"S Willier","year":"2013","unstructured":"Willier S, Butt E, Grunewald TG . Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell 2013; 105: 317\u2013333.","journal-title":"Biol Cell"},{"key":"BFonc2016244_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/ng.1085","volume":"44","author":"S Postel-Vinay","year":"2012","unstructured":"Postel-Vinay S, Veron AS, Tirode F, Pierron G, Reynaud S, Kovar H et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet 2012; 44: 323\u2013327.","journal-title":"Nat Genet"},{"key":"BFonc2016244_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fonc.2015.00162","volume":"5","author":"F Cidre-Aranaz","year":"2015","unstructured":"Cidre-Aranaz F, Alonso J . EWS\/FLI1 target genes and therapeutic opportunities in Ewing sarcoma. Front Oncol 2015; 5: 162.","journal-title":"Front Oncol"},{"key":"BFonc2016244_CR30","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1101\/gr.151340.112","volume":"23","author":"S Bilke","year":"2013","unstructured":"Bilke S, Schwentner R, Yang F, Kauer M, Jug G, Walker RL et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res 2013; 23: 1797\u20131809.","journal-title":"Genome Res"},{"key":"BFonc2016244_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2014.10.004","volume":"26","author":"N Riggi","year":"2014","unstructured":"Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suva ML et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 2014; 26: 668\u2013681.","journal-title":"Cancer Cell"},{"key":"BFonc2016244_CR32","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.celrep.2015.01.042","volume":"10","author":"EM Tomazou","year":"2015","unstructured":"Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Schonegger A, Datlinger P et al. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep 2015; 10: 1082\u20131095.","journal-title":"Cell Rep"},{"key":"BFonc2016244_CR33","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1172\/JCI31457","volume":"117","author":"DF Calvisi","year":"2007","unstructured":"Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117: 2713\u20132722.","journal-title":"J Clin Invest"},{"key":"BFonc2016244_CR34","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1038\/onc.2011.556","volume":"31","author":"A Macia","year":"2012","unstructured":"Macia A, Gallel P, Vaquero M, Gou-Fabregas M, Santacana M, Maliszewska A et al. Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma. Oncogene 2012; 31: 3961\u20133972.","journal-title":"Oncogene"},{"key":"BFonc2016244_CR35","doi-asserted-by":"publisher","first-page":"46460","DOI":"10.1074\/jbc.M108234200","volume":"276","author":"I Gross","year":"2001","unstructured":"Gross I, Bassit B, Benezra M, Licht JD . Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem 2001; 276: 46460\u201346468.","journal-title":"J Biol Chem"},{"key":"BFonc2016244_CR36","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1007\/s13277-014-1665-y","volume":"35","author":"AH Mekkawy","year":"2014","unstructured":"Mekkawy AH, Pourgholami MH, Morris DL . Human Sprouty1 suppresses growth, migration, and invasion in human breast cancer cells. Tumour Biol 2014; 35: 5037\u20135048.","journal-title":"Tumour Biol"},{"key":"BFonc2016244_CR37","doi-asserted-by":"publisher","first-page":"e59369","DOI":"10.1371\/journal.pone.0059369","volume":"8","author":"ET Wiles","year":"2013","unstructured":"Wiles ET, Lui-Sargent B, Bell R, Lessnick SL . BCL11B is up-regulated by EWS\/FLI and contributes to the transformed phenotype in Ewing sarcoma. PLoS ONE 2013; 8: e59369.","journal-title":"PLoS ONE"},{"key":"BFonc2016244_CR38","first-page":"683","volume":"4","author":"X Liu","year":"2014","unstructured":"Liu X, Lan Y, Zhang D, Wang K, Wang Y, Hua ZC . SPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferation. Am J Cancer Res 2014; 4: 683\u2013697.","journal-title":"Am J Cancer Res"},{"key":"BFonc2016244_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1677\/erc.0.0070165","volume":"7","author":"CJ Powers","year":"2000","unstructured":"Powers CJ, McLeskey SW, Wellstein A . Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165\u2013197.","journal-title":"Endocr Relat Cancer"},{"key":"BFonc2016244_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1210\/er.2003-0040","volume":"26","author":"RT Bottcher","year":"2005","unstructured":"Bottcher RT, Niehrs C . Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 2005; 26: 63\u201377.","journal-title":"Endocr Rev"},{"key":"BFonc2016244_CR41","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.biocel.2008.11.008","volume":"41","author":"G Chalkiadaki","year":"2009","unstructured":"Chalkiadaki G, Nikitovic D, Berdiaki A, Sifaki M, Krasagakis K, Katonis P et al. Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism. Int J Biochem Cell Biol 2009; 41: 1323\u20131331.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFonc2016244_CR42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1073\/pnas.91.2.484","volume":"91","author":"F Yamaguchi","year":"1994","unstructured":"Yamaguchi F, Saya H, Bruner JM, Morrison RS . Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 1994; 91: 484\u2013488.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016244_CR43","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","volume":"21","author":"M Touat","year":"2015","unstructured":"Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC . Targeting FGFR signaling in cancer. Clin Cancer Res 2015; 21: 2684\u20132694.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016244_CR44","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/sj.bjc.6605775","volume":"103","author":"S Kamura","year":"2010","unstructured":"Kamura S, Matsumoto Y, Fukushi JI, Fujiwara T, Iida K, Okada Y et al. Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing\u2019s sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway. Br J Cancer 2010; 103: 370\u2013381.","journal-title":"Br J Cancer"},{"key":"BFonc2016244_CR45","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1158\/1078-0432.CCR-14-2744","volume":"21","author":"K Agelopoulos","year":"2015","unstructured":"Agelopoulos K, Richter GH, Schmidt E, Dirksen U, von Heyking K, Moser B et al. Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma. Clin Cancer Res 2015; 21: 4935\u20134946.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016244_CR46","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/2159-8290.CD-14-0622","volume":"4","author":"F Tirode","year":"2014","unstructured":"Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 2014; 4: 1342\u20131353.","journal-title":"Cancer Discov"},{"key":"BFonc2016244_CR47","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1038\/sj.onc.1201397","volume":"15","author":"H Kovar","year":"1997","unstructured":"Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997; 15: 2225\u20132232.","journal-title":"Oncogene"},{"key":"BFonc2016244_CR48","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1038\/sj.onc.1206391","volume":"22","author":"H Kovar","year":"2003","unstructured":"Kovar H, Pospisilova S, Jug G, Printz D, Gadner H . Response of Ewing tumor cells to forced and activated p53 expression. Oncogene 2003; 22: 3193\u20133204.","journal-title":"Oncogene"},{"key":"BFonc2016244_CR49","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 2015; 33: 3036\u20133046.","journal-title":"J Clin Oncol"},{"key":"BFonc2016244_CR50","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/jcb.24805","volume":"115","author":"N Terada","year":"2014","unstructured":"Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Liu Z, Takahashi S et al. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. J Cell Biochem 2014; 115: 1505\u20131515.","journal-title":"J Cell Biochem"},{"key":"BFonc2016244_CR51","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/ijc.21578","volume":"118","author":"M Mendiola","year":"2006","unstructured":"Mendiola M, Carrillo J, Garcia E, Lalli E, Hernandez T, de Alava E et al. The orphan nuclear receptor DAX1 is up-regulated by the EWS\/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 2006; 118: 1381\u20131389.","journal-title":"Int J Cancer"},{"key":"BFonc2016244_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/1087057110361772","volume":"15","author":"PY Yue","year":"2010","unstructured":"Yue PY, Leung EP, Mak NK, Wong RN . A simplified method for quantifying cell migration\/wound healing in 96-well plates. J Biomol Screen 2010; 15: 427\u2013433.","journal-title":"J Biomol Screen"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2016244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016244","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T21:05:21Z","timestamp":1647896721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2016244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,4]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2,9]]}},"alternative-id":["BFonc2016244"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.244","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,4]]},"assertion":[{"value":"5 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}